The Experts below are selected from a list of 996 Experts worldwide ranked by ideXlab platform
Takanori Ishida - One of the best experts on this subject based on the ideXlab platform.
-
^18F-fluorodeoxyglucose specimen-Positron Emission Mammography delineates tumour extension in breast-conserving surgery: Preliminary results
European Radiology, 2018Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (^18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff. Methods Sixteen patients underwent Positron Emission tomography, and then BCS with intraoperative frozen section analysis on the same day. Resected specimens with remaining ^18F-FDG accumulation were scanned by high-resolution PEM. At least 1 day after surgery, tumour extension was evaluated by three independent experienced readers and by binarized images from the specimen-PEM data. Intraoperative exposure of medical staff to ^18F-FDG was measured. Results Specimen-PEM evaluations of binarized images and the three investigators detected all (100 %, 12/12) invasive lesions and 94.4 % (17/18) of in situ lesions using both methods. The positive predictive value of the accumulated lesions was 74.4 % (29/39) for the binarized images and 82.9 % (29/35) for the three investigators. Analysis of intraoperative frozen sections detected 100 % (2/2) of the margin-positive cases, also detected by both specimen-PEM evaluation methods with no false-positive margin cases. The mean exposure of the medical staff to ^18F was 18 μSv. Conclusions Specimen-PEM detected invasive and in situ lesions with high accuracy and allowable radiation exposure. Key points • Specimen-PEM detected invasive and in situ lesions with high accuracy. • Specimen-PEM predicted complete resection with the same accuracy as frozen section analysis. • Breast-conserving surgery after fluorodeoxyglucose injection was performed with low medical staff exposure.
-
18 f fluorodeoxyglucose specimen Positron Emission Mammography delineates tumour extension in breast conserving surgery preliminary results
European Radiology, 2018Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff.
-
Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer
The Tohoku Journal of Experimental Medicine, 2018Co-Authors: Ai Yanai, Masatoshi Itoh, Noriaki Ohuchi, Seiichi Yamamoto, Manabu Tashiro, Akira Yoshikawa, Hisashi Hirakawa, Kazuhiko Yanai, Ryuichi Harada, Takanori IshidaAbstract:Positron Emission Mammography (PEM) has higher detection sensitivity for breast cancer compared with whole-body Positron Emission tomography (PET) due to higher spatial resolution. We have developed a new PEM device with high resolution over a wide field of view. This PEM device comprises novel scintillation crystals, praseodymium-doped lutetium aluminum garnet (Pr:LuAG). In the present study, the clinical use of the newly developed PEM for the detection of small breast cancer was compared with that of the conventional PET-computed tomography (PET/CT). Eighty-two patients with breast cancer less than 20 mm (UICC T1) participated in this study, including 23 patients with T1a or T1b breast cancer (less than 10 mm). Histologically-proved lesions were examined by PET/CT and PEM on the same day after injection of [18F]fluoro-2-deoxy-2-fluoro-D-glucose ([18F]FDG), a marker of glycolytic activity. The newly developed PEM showed better sensitivity of cancer detection compared with PET/CT especially in case of the small T1a or T1b lesions. Moreover, when the conventional PET/CT and new PEM were combined, the detection sensitivity with [18F]FDG molecular imaging for T1 (N = 82) and T1a plus T1b breast cancer (N = 23) were 90% and 70%, respectively. The uptake of [18F]FDG was proportional to the histological malignancy of breast cancer. Using the newly-developed PEM with [18F]FDG, we are able to identify and characterize exactly the small breast tumors less than 10 mm in combination with the conventional PET/CT. These data indicate that PEM and PET/CT are synergic and complementary for the detection of small breast cancer.
-
18F-fluorodeoxyglucose specimen-Positron Emission Mammography delineates tumour extension in breast-conserving surgery: Preliminary results.
European Radiology, 2017Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff.
Gou Watanabe - One of the best experts on this subject based on the ideXlab platform.
-
18 f fluorodeoxyglucose specimen Positron Emission Mammography delineates tumour extension in breast conserving surgery preliminary results
European Radiology, 2018Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff.
-
^18F-fluorodeoxyglucose specimen-Positron Emission Mammography delineates tumour extension in breast-conserving surgery: Preliminary results
European Radiology, 2018Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (^18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff. Methods Sixteen patients underwent Positron Emission tomography, and then BCS with intraoperative frozen section analysis on the same day. Resected specimens with remaining ^18F-FDG accumulation were scanned by high-resolution PEM. At least 1 day after surgery, tumour extension was evaluated by three independent experienced readers and by binarized images from the specimen-PEM data. Intraoperative exposure of medical staff to ^18F-FDG was measured. Results Specimen-PEM evaluations of binarized images and the three investigators detected all (100 %, 12/12) invasive lesions and 94.4 % (17/18) of in situ lesions using both methods. The positive predictive value of the accumulated lesions was 74.4 % (29/39) for the binarized images and 82.9 % (29/35) for the three investigators. Analysis of intraoperative frozen sections detected 100 % (2/2) of the margin-positive cases, also detected by both specimen-PEM evaluation methods with no false-positive margin cases. The mean exposure of the medical staff to ^18F was 18 μSv. Conclusions Specimen-PEM detected invasive and in situ lesions with high accuracy and allowable radiation exposure. Key points • Specimen-PEM detected invasive and in situ lesions with high accuracy. • Specimen-PEM predicted complete resection with the same accuracy as frozen section analysis. • Breast-conserving surgery after fluorodeoxyglucose injection was performed with low medical staff exposure.
-
18F-fluorodeoxyglucose specimen-Positron Emission Mammography delineates tumour extension in breast-conserving surgery: Preliminary results.
European Radiology, 2017Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff.
Christopher J Thompson - One of the best experts on this subject based on the ideXlab platform.
-
Evolution and Developments in Instrumentation for Positron Emission Mammography.
PET Clinics, 2009Co-Authors: Habib Zaidi, Christopher J ThompsonAbstract:Molecular imaging using high-resolution PET instrumentation is now playing a pivotal role in basic and clinical research. The development of optimized detection geometries combined with high-performance detector technologies and compact designs of PET tomographs have become the goal of active research groups in academic and corporate settings. Significant progress has been achieved in the design of commercial PET instrumentation in the last decade allowing a spatial resolution of about 4 to 6 mm to be reached for whole-body imaging, about 2.4 mm for PET cameras dedicated for brain imaging, and submillimeter resolution for female breast, prostate, and small-animal imaging. In particular, significant progress has been made in the design of dedicated Positron Emission Mammography (PEM) units. The initial concept suggested in 1993 consisted of placing 2 planar detectors capable of detecting the 511-keV annihilation photons in a conventional Mammography unit. Since that time, many different design paths have been pursued and it will be interesting to see which technologies become the most successful in the future. This paper discusses recent advances in PEM instrumentation and the advantages and challenges of dedicated standalone and dual-modality imaging systems. Future opportunities and the challenges facing the adoption of PEM imaging instrumentation and its role in clinical and research settings are also addressed.
-
Technique to obtain Positron Emission Mammography images in registration with x-ray mammograms
Medical Physics, 1998Co-Authors: Alanah M. Bergman, Kavita Murthy, Michael J. English, Antoine Loutfi, Raymond L. Clancy, James L. Robar, Christopher J Thompson, R Lisbona, Jean GagnonAbstract:X-ray mammograms reveal abnormal tissue densities, while metabolic images identify regions of abnormal metabolism. Conventional nuclear medicine and radiologic breast images must be acquired at different times with different patient positions making coregistration difficult. Accurate coregistration of metabolic and x-ray images of the breast is likely to be important when acquiring information about the location and diagnosis of suspicious lesions or tumors. Our PEM-1 (Positron Emission Mammography) system detects metabolic activity within the breast. The two planar detectors are integrated into a conventional x-ray Mammography unit. This arrangement simplifies the image registration process by allowing a breast metabolic image to be acquired immediately after performing an x-ray mammogram. The patient is not moved between procedures. A coregistration tool has also been developed. A thin plastic sheet with a wire frame protrudes from the side of the upper PEM detector. With the tool positioned over the suspicious area of the breast, a magnified film density image is made using the available x-ray equipment. A radio-opaque rectangular outline of the wire frame is visible on the film image. During a Positron Emission metabolic scan, detectors acquire a 49 x 59 mm2 image of the same region. The PEM detectors can be positioned anywhere along the width of the breast. This provides an image of a particular region of interest. Several contiguous images may be combined to provide a complete scan.
-
Imaging performance of PEM-1: a high resolution system for Positron Emission Mammography
1995 IEEE Nuclear Science Symposium and Medical Imaging Conference Record, 1Co-Authors: Christopher J Thompson, Alanah M. Bergman, Antoine Loutfi, James L. Robar, R Lisbona, K. Murthy, I.n. Weinberg, Jean H. Gagnon, R.l. Clancy, R. MakoAbstract:Positron Emission tomography with /sup 18/F-fluoro-deoxyglucose (FDG) is known to detect the increased metabolism of breast tumours. The authors have built a Positron Emission Mammography system which produces metabolic breast images co-registered with conventional Mammography. Two position sensitive photomultipliers are coupled to four BGO blocks which are partially cut into 2/spl times/2 mm elements from both faces. This provides 72/spl times/72 BGO crystals in coincidence yielding over 26 million lines of response. A real time display is formed by performing a weighted back-projection onto seven image planes through the breast. The prototype instrument is currently being tested on phantoms. The spatial resolution in the central region has been measured at 2.05 mm FWHM, less than half that of a conventional PET scanner. The coincidence resolving time is 12 nsec. This device should be able to identify breast tumours
-
Positron Emission Mammography (PEM): a promising technique for detecting breast cancer
Proceedings of 1994 IEEE Nuclear Science Symposium - NSS'94, 1Co-Authors: Christopher J Thompson, K. Murthy, I.n. Weinberg, Y. Picard, R. MakoAbstract:The authors are developing a high specificity technique for detecting the increased metabolic rate of breast tumours. The glucose analog FDG is known to concentrate in breast tumours rendering them easily detectable in conventional PET scans. Since PET is a relatively expensive imaging technique it is not been used routinely in the detection of breast cancer. Positron Emission Mammography (PEM) will provide a highly efficient, high spatial resolution, and low cost Positron imaging system whose metabolic images are co-registered with conventional Mammography. Coincidences between two BGO blocks cut into 2/spl times/2 mm squares coupled to two 7.5 cm square imaging PMTs are detected and back-projected to form real-time multiple plane images. The design is about 20 times more sensitive than a conventional multi-slice PET body scanner, so much less radiopharmaceutical can be used, reducing the patient dose and cost per scan. Prototype detectors have been made and extensive measurements done. The device is expected to have an in-plane spatial resolution about 2 mm FWHM. Besides the application as a secondary screening tool the device may be beneficial in measuring a tumour's response to radiotherapy or chemotherapy, as well as aiding the surgeon in optimizing the removal of malignant tissue. >
-
Co-registration of Positron Emission Mammography (PEM) images and X-ray mammograms
1996 IEEE Nuclear Science Symposium. Conference Record, 1Co-Authors: Alanah M. Bergman, James L. Robar, Christopher J Thompson, K. Murthy, R.l. ClancyAbstract:Accurate co-registration of metabolic and X-ray images of the breast is important when acquiring information about the location and diagnosis of suspicious lesions or tumours. X-ray mammograms reveal abnormal tissue densities, while metabolic images identify regions of abnormal metabolism. Conventional nuclear medicine and radiologic breast images must be acquired at different times with different patient positions making co-registration difficult. Positron Emission Mammography (PEM) simplifies the image registration process by acquiring both an X-ray density image and a metabolic image consecutively, without moving the patient between scans. The authors have integrated PEM detectors into a conventional mammographic unit and they have developed a co-registration tool. The tool is a thin sheet of plexiglass (130/spl times/95/spl times/3 mm/sup 3/) with a 49/spl times/39 mm/sup 2/ window. The tool protrudes from the side of the upper PEM detector. The suspicious area of the breast is imaged through this tool during a magnified X-ray mammogram, producing a radiolucent region on the resulting film image. During a Positron Emission scan, detectors acquire an image of the same region. The PEM detectors can be positioned anywhere along the width of the breast to provide a complete scan.
I.n. Weinberg - One of the best experts on this subject based on the ideXlab platform.
-
Applications for Positron Emission Mammography
Physica Medica, 2006Co-Authors: I.n. WeinbergAbstract:High resolution Positron Emission Mammography (PEM) can address the current clinical needs of breast cancer patients and the requirements for future translational work. Combining the quantitative capabilities of Positron Emission tomography (PET) with millimeter resolution, PEM can image the earliest in situ forms of breast cancer as well as putative cancer precursor lesions (e.g., atypical ductal hyperplasia) whose behavior is important for prevention studies. The importance of the ability to detect intraductal cancer cannot be overemphasized, for several reasons: at least one-third of new cancers are detected at this intraductal stage, intervention at this stage represents the best opportunity for complete cure, and a significant number of invasive cancers contain an intraductal component. Without knowledge of the extent of the intraductal component, surgeons are unable to completely excise cancers about a third of the time, leading to unnecessary re-excisions or radiation therapy. Current investigations aimed at specifying best practices in radiotherapy of DCIS patients are stymied by the lack of objective quantitative methods of rapidly assessing response. Other future applications of PEM are suggested, including an information technology project built on PEM that promises to individualize therapy and facilitate surveillance of high risk populations. The high overall accuracy of PEM (i.e., both specificity and sensitivity) is an unusual and welcome development in the history of breast imaging. With this high accuracy, and continued technical innovation to reduce radiation dose, PEM may someday replace X-ray Mammography as a first line approach to breast cancer detection.
-
Positron Emission Mammography: high-resolution biochemical breast imaging.
Technology in Cancer Research & Treatment, 2005Co-Authors: I.n. Weinberg, Valera Zavarzin, Deepa Narayanan, David Beylin, Steve Yarnall, Pavel Stepanov, E.v. Anashkin, Sergei Dolinsky, Kathrin Lauckner, Lee P. AdlerAbstract:Positron Emission Mammography (PEM) provides images of biochemical activity in the breast with spatial resolution matching individual ducts (1.5 mm full-width at half-maximum). This spatial resolution, supported by count efficiency that results in high signal-to-noise ratio, allows confident visualization of intraductal as well as invasive breast cancers. Clinical trials with a full-breast PEM device have shown high clinical accuracy in characterizing lesions identified as suspicious on the basis of conventional imaging or physical examination (sensitivity 93%, specificity 83%, area under the ROC curve of 0.93), with high sensitivity preserved (91%) for intraductal cancers. Increased sensitivity did not come at a cost of reduced specificity. Considering that intraductal cancer represents more than 30% of reported cancers, and is the form of cancer with the highest probability of achieving surgical cure, it is likely that the use of PEM will complement anatomic imaging modalities in the areas of surgical planning, high-risk monitoring, and minimally invasive therapy. The quantitative nature of PET promises to assist researchers interested studying the response of putative cancer precursors (e.g., atypical ductal hyperplasia) to candidate prevention agents.
-
Pilot clinical trial of 18F-fluorodeoxyglucose Positron-Emission Mammography in the surgical management of breast cancer
The American Journal of Surgery, 2005Co-Authors: Lorraine Tafra, Edward A. Levine, Deepa Narayanan, I.n. Weinberg, Wendie A. Berg, Zandra Cheng, Joseph Uddo, Mary Beth Lobrano, William Stein, Eric A. RossAbstract:Abstract Background High-resolution Positron-Emission Mammography (PEM) is a new device, which allows the imaging of breast tissue. A prospective study was performed to assess the accuracy of PEM in newly diagnosed breast cancer patients. Methods In a prospective multicenter study, 44 women with confirmed breast cancers were imaged with a high-resolution PEM scanner (Naviscan PET Systems, Rockville, MD) with 18F-fluorodeoxyglucose. The images were blindly evaluated and were compared with final pathology. Results The majority of the index lesions were seen on PEM (89%, 39/44). PEM detected 4 of 5 incidental breast cancers, 3 of which were not seen by any other imaging modalities. Of 19 patients undergoing breast-conserving surgery, PEM correctly predicted 6 of 8 (75%) patients with positive margins and 100% (11/11) with negative margins. Conclusion The current PEM device shows promise in detecting breast malignancies and may assist in the planning of adequate partial mastectomy procedures to better ensure negative margins.
-
imaging performance of pem 1 a high resolution system for Positron Emission Mammography
Nuclear Science Symposium and Medical Imaging Conference, 1995Co-Authors: C. J. Thompson, Alanah M. Bergman, Antoine Loutfi, James L. Robar, R Lisbona, K. Murthy, I.n. Weinberg, Jean H. Gagnon, R.l. Clancy, R. MakoAbstract:Positron Emission tomography with /sup 18/F-fluoro-deoxyglucose (FDG) is known to detect the increased metabolism of breast tumours. The authors have built a Positron Emission Mammography system which produces metabolic breast images co-registered with conventional Mammography. Two position sensitive photomultipliers are coupled to four BGO blocks which are partially cut into 2/spl times/2 mm elements from both faces. This provides 72/spl times/72 BGO crystals in coincidence yielding over 26 million lines of response. A real time display is formed by performing a weighted back-projection onto seven image planes through the breast. The prototype instrument is currently being tested on phantoms. The spatial resolution in the central region has been measured at 2.05 mm FWHM, less than half that of a conventional PET scanner. The coincidence resolving time is 12 nsec. This device should be able to identify breast tumours <5 mm in diameter and provide 3-D localization registered with conventional Mammography.
-
Feasibility study for Positron Emission Mammography
Medical Physics, 1994Co-Authors: C. J. Thompson, K. Murthy, I.n. Weinberg, F. MakoAbstract:A feasibility study is presented for a small, low‐cost, dedicated device for Positron Emission Mammography. Two detector arrays above and below the breast would be placed in a conventional Mammography unit. These detectors are sensitive to Positron annihilation radiation, and are connected to a coincidence circuit and a multiplane image memory. Images of the distribution of Positron‐emitting isotope are obtained in real time by incrementing the memory location at the intersection of each line of response. Monte Carlo simulations of a breast phantom are compared with actual scans of this phantom in a conventional PET scanner. The simulations and experimental data are used to predict the performance of the proposed system. Spatial resolution experiments using very narrow bismuth germanate BGO crystals suggest that spatial resolutions of about 2 mm should be possible. The efficiency of the proposed device is about ten times that of a conventional brain scanner. The scatter fraction is greater, but the scattered radiation has a very flat distribution. By designing the device to fit in an existing Mammography unit, conventional mammograms can be taken after the injection of the radio‐pharmaceutical allowing exact registration of the Emission and conventional mammographicimages.
Noriaki Ohuchi - One of the best experts on this subject based on the ideXlab platform.
-
^18F-fluorodeoxyglucose specimen-Positron Emission Mammography delineates tumour extension in breast-conserving surgery: Preliminary results
European Radiology, 2018Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (^18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff. Methods Sixteen patients underwent Positron Emission tomography, and then BCS with intraoperative frozen section analysis on the same day. Resected specimens with remaining ^18F-FDG accumulation were scanned by high-resolution PEM. At least 1 day after surgery, tumour extension was evaluated by three independent experienced readers and by binarized images from the specimen-PEM data. Intraoperative exposure of medical staff to ^18F-FDG was measured. Results Specimen-PEM evaluations of binarized images and the three investigators detected all (100 %, 12/12) invasive lesions and 94.4 % (17/18) of in situ lesions using both methods. The positive predictive value of the accumulated lesions was 74.4 % (29/39) for the binarized images and 82.9 % (29/35) for the three investigators. Analysis of intraoperative frozen sections detected 100 % (2/2) of the margin-positive cases, also detected by both specimen-PEM evaluation methods with no false-positive margin cases. The mean exposure of the medical staff to ^18F was 18 μSv. Conclusions Specimen-PEM detected invasive and in situ lesions with high accuracy and allowable radiation exposure. Key points • Specimen-PEM detected invasive and in situ lesions with high accuracy. • Specimen-PEM predicted complete resection with the same accuracy as frozen section analysis. • Breast-conserving surgery after fluorodeoxyglucose injection was performed with low medical staff exposure.
-
18 f fluorodeoxyglucose specimen Positron Emission Mammography delineates tumour extension in breast conserving surgery preliminary results
European Radiology, 2018Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff.
-
Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer
The Tohoku Journal of Experimental Medicine, 2018Co-Authors: Ai Yanai, Masatoshi Itoh, Noriaki Ohuchi, Seiichi Yamamoto, Manabu Tashiro, Akira Yoshikawa, Hisashi Hirakawa, Kazuhiko Yanai, Ryuichi Harada, Takanori IshidaAbstract:Positron Emission Mammography (PEM) has higher detection sensitivity for breast cancer compared with whole-body Positron Emission tomography (PET) due to higher spatial resolution. We have developed a new PEM device with high resolution over a wide field of view. This PEM device comprises novel scintillation crystals, praseodymium-doped lutetium aluminum garnet (Pr:LuAG). In the present study, the clinical use of the newly developed PEM for the detection of small breast cancer was compared with that of the conventional PET-computed tomography (PET/CT). Eighty-two patients with breast cancer less than 20 mm (UICC T1) participated in this study, including 23 patients with T1a or T1b breast cancer (less than 10 mm). Histologically-proved lesions were examined by PET/CT and PEM on the same day after injection of [18F]fluoro-2-deoxy-2-fluoro-D-glucose ([18F]FDG), a marker of glycolytic activity. The newly developed PEM showed better sensitivity of cancer detection compared with PET/CT especially in case of the small T1a or T1b lesions. Moreover, when the conventional PET/CT and new PEM were combined, the detection sensitivity with [18F]FDG molecular imaging for T1 (N = 82) and T1a plus T1b breast cancer (N = 23) were 90% and 70%, respectively. The uptake of [18F]FDG was proportional to the histological malignancy of breast cancer. Using the newly-developed PEM with [18F]FDG, we are able to identify and characterize exactly the small breast tumors less than 10 mm in combination with the conventional PET/CT. These data indicate that PEM and PET/CT are synergic and complementary for the detection of small breast cancer.
-
18F-fluorodeoxyglucose specimen-Positron Emission Mammography delineates tumour extension in breast-conserving surgery: Preliminary results.
European Radiology, 2017Co-Authors: Gou Watanabe, Masatoshi Itoh, X. Duan, Hiroshi Watabe, Naoko Mori, Hiroshi Tada, Akihiko Suzuki, Minoru Miyashita, Noriaki Ohuchi, Takanori IshidaAbstract:Objectives We aimed to determine whether high-resolution specimen-Positron Emission Mammography (PEM) using fluorodeoxyglucose (18F-FDG) can reveal extension of breast cancer in breast-conserving surgery (BCS), and assess the safety of radiation exposure to medical staff.